These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36140519)

  • 1. Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab.
    Fabbi M; Costa D; Russo D; Arenare L; Gaggero G; Signoriello S; Scambia G; Pisano C; Colombo N; Losito NS; Filaci G; Spina A; Califano D; Scognamiglio G; Gadducci A; Mezzanzanica D; Bagnoli M; Ferrini S; Canzonieri V; Chiodini P; Perrone F; Pignata S
    Diagnostics (Basel); 2022 Aug; 12(9):. PubMed ID: 36140519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel marker ADAM17 for clear cell renal cell carcinomas: implication for patients' prognosis.
    Li G; Forest F; Feng G; Gentil-Perret A; Péoc'h M; Cottier M; Mottet N
    Urol Oncol; 2014 Nov; 32(8):1272-6. PubMed ID: 24996774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
    Daniele G; Raspagliesi F; Scambia G; Pisano C; Colombo N; Frezzini S; Tognon G; Artioli G; Gadducci A; Lauria R; Ferrero A; Cinieri S; De Censi A; Breda E; Scollo P; De Giorgi U; Lissoni AA; Katsaros D; Lorusso D; Salutari V; Cecere SC; Zaccarelli E; Nardin M; Bogani G; Distefano M; Greggi S; Piccirillo MC; Fossati R; Giannone G; Arenare L; Gallo C; Perrone F; Pignata S
    Int J Gynecol Cancer; 2021 Jun; 31(6):875-882. PubMed ID: 33931498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients.
    D'Alterio C; Spina A; Arenare L; Chiodini P; Napolitano M; Galdiero F; Portella L; Simeon V; Signoriello S; Raspagliesi F; Lorusso D; Pisano C; Colombo N; Zannoni GF; Losito NS; De Cecio R; Scognamiglio G; Califano D; Russo D; Tuninetti V; Piccirillo MC; Gargiulo P; Perrone F; Pignata S; Scala S
    Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer.
    Zhang L; Zhou Q
    Eur J Pharmacol; 2018 Oct; 837():64-71. PubMed ID: 30059681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer.
    Yasunaga M; Yahata H; Okugawa K; Shimokawa M; Maeda Y; Hori E; Kodama K; Yagi H; Ohgami T; Onoyama I; Asanoma K; Kato K
    Taiwan J Obstet Gynecol; 2022 Sep; 61(5):818-822. PubMed ID: 36088050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.
    Geng N; Su J; Liu Z; Ding C; Xie S; Hu W
    Technol Cancer Res Treat; 2021; 20():15330338211019433. PubMed ID: 34060368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy.
    Aydin D; Bilici A; Yavuzer D; Kefeli U; Tan A; Ercelep O; Mert A; Yuksel S; Ozcelik M; Isik D; Surmeli H; Odabasi H; Aliustaoglu M
    Clin Transl Oncol; 2015 Aug; 17(8):604-11. PubMed ID: 25786367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study.
    Califano D; Gallo D; Rampioni Vinciguerra GL; De Cecio R; Arenare L; Signoriello S; Russo D; Ferrandina G; Citron F; Losito NS; Gargiulo P; Simeon V; Scambia G; Cecere SC; Montella M; Colombo N; Tognon G; Bignotti E; Zannoni GF; Canzonieri V; Ciucci A; Spina A; Scognamiglio G; Del Sesto M; Schettino C; Piccirillo MC; Perrone F; Chiodini P; Pignata S; Baldassarre G
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
    Trillsch F; Mahner S; Hilpert F; Davies L; García-Martínez E; Kristensen G; Savarese A; Vuylsteke P; Los M; Zagouri F; Gladieff L; Sehouli J; Khoon Lee C; Gebski V; Pujade-Lauraine E
    Ann Oncol; 2016 Sep; 27(9):1733-9. PubMed ID: 27287207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADAM17 inhibition enhances platinum efficiency in ovarian cancer.
    Hedemann N; Rogmans C; Sebens S; Wesch D; Reichert M; Schmidt-Arras D; Oberg HH; Pecks U; van Mackelenbergh M; Weimer J; Arnold N; Maass N; Bauerschlag DO
    Oncotarget; 2018 Mar; 9(22):16043-16058. PubMed ID: 29662625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients.
    Hansen MKG; Smerdel MP; Waldstrøm M; Andersen RF; Adimi P; Jakobsen A; Steffensen KD
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):751-759. PubMed ID: 33067703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer.
    Shou ZX; Jin X; Zhao ZS
    Ann Surg; 2012 Dec; 256(6):1014-22. PubMed ID: 22668812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of ADAM17 in human gastric cancer.
    Zhang TC; Zhu WG; Huang MD; Fan RH; Chen XF
    Med Oncol; 2012 Dec; 29(4):2684-90. PubMed ID: 22139867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADAM17 Inhibition Increases the Impact of Cisplatin Treatment in Ovarian Cancer Spheroids.
    Hedemann N; Herz A; Schiepanski JH; Dittrich J; Sebens S; Dempfle A; Feuerborn J; Rogmans C; Tribian N; Flörkemeier I; Weimer J; Krüger S; Maass N; Bauerschlag DO
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.
    Daniele G; Lorusso D; Scambia G; Cecere SC; Nicoletto MO; Breda E; Colombo N; Artioli G; Cannella L; Lo Re G; Raspagliesi F; Maltese G; Salutari V; Ferrandina G; Greggi S; Baldoni A; Bergamini A; Piccirillo MC; Tognon G; Floriani I; Signoriello S; Perrone F; Pignata S
    Gynecol Oncol; 2017 Feb; 144(2):256-259. PubMed ID: 27993479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab.
    Hoang T; Dahlberg SE; Sandler AB; Brahmer JR; Schiller JH; Johnson DH
    J Thorac Oncol; 2012 Sep; 7(9):1361-8. PubMed ID: 22843087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma.
    Xu Q; Ying M; Chen G; Lin A; Xie Y; Ohara N; Zhou D
    Tumour Biol; 2014 Aug; 35(8):7575-86. PubMed ID: 24793016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.
    Eichbaum MH; Weiss LM; Bruckner T; Schneeweiss A; Sinn HP; Gebauer G; Fersis N; Kussmaul J; Sohn C
    Med Sci Monit; 2009 Apr; 15(4):CR156-63. PubMed ID: 19333199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
    Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
    Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.